PMID: 11823257Feb 2, 2002Paper

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials

The American Journal of Psychiatry
Stefan LeuchtWerner Kissling


The "atypical" profile of the new antipsychotics clozapine, olanzapine, quetiapine, and risperidone has been linked to combined antagonism of serotonin 2 (5-HT(2)) and dopamine 2 (D(2)) receptors. Although amisulpride is a highly selective D(3)/D(2) receptor antagonist, it is assumed to have atypical properties as well. The purpose of this article was to compare the atypical profile of amisulpride with that of the 5-HT(2)/D(2) antagonists. Randomized controlled trials that compared amisulpride with conventional antipsychotics or placebo for patients with schizophrenia were identified and included in a meta-analysis. The mean effect sizes found for amisulpride were compared with those of an updated meta-analysis of the 5-HT(2)/D(2) antagonists. Eighteen randomized controlled trials of amisulpride (N=2,214) were found. In 11 studies of acutely ill patients it proved to be consistently more effective than conventional antipsychotics for global schizophrenic symptoms (measured with the Brief Psychiatric Rating Scale) and negative symptoms. Amisulpride is to date the only atypical antipsychotic for which several studies of patients suffering predominantly from negative symptoms have been published. In four such studies amisulpride w...Continue Reading


Dec 17, 2002·Pharmazie in unserer Zeit·Walter E Müller
Jul 10, 2007·Psychopharmacology·Stefan LeuchtWerner Kissling
Apr 2, 2009·Psychopharmacology·Atheir I AbbasBryan L Roth
Jul 5, 2005·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Oct 25, 2003·European Journal of Pharmacology·Tal WeizmanShaul Schreiber
Apr 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·N BergemannA Frick
Feb 19, 2004·European Psychiatry : the Journal of the Association of European Psychiatrists·Mathias ZinkJohannes Thome
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shitij Kapur, David Mamo
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hans-Jürgen Möller
Aug 27, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan Leucht, Rolf R Engel
Feb 9, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan LeuchtStefan Wagenpfeil
Feb 3, 2006·The New England Journal of Medicine·John M Davis
Oct 31, 2003·The New England Journal of Medicine·Robert Freedman
May 14, 2008·The Australian and New Zealand Journal of Psychiatry·Wing King LeeChi Chiu Lee
Aug 15, 2006·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Jun 15, 2007·Schizophrenia Bulletin·Carol A Tamminga, John M Davis
Feb 1, 2008·Schizophrenia Bulletin·Stefan LeuchtJohn M Kane
Apr 13, 2004·International Clinical Psychopharmacology·Ann MortimerUNKNOWN SOLIANOL Sudy Group
Dec 17, 2004·International Clinical Psychopharmacology·M C Jockers-ScherüblP Schlattmann
Mar 11, 2006·International Clinical Psychopharmacology·Jean-Pierre OliéRuoyong Yang
May 27, 2010·Clinical Neuropharmacology·Artemios PehlivanidisGeorge N Papadimitriou
Mar 12, 2008·Current Opinion in Psychiatry·Christoph U Correll, Eva M Schenk
Apr 7, 2007·International Clinical Psychopharmacology·Joseph PeuskensUNKNOWN SOLIANOL Study Group
May 24, 2007·International Clinical Psychopharmacology·Francesca BrambillaPalmiero Monteleone
Jan 19, 2012·Psychiatry and Clinical Neurosciences·Bun-Hee LeeYoung-Min Park
Jul 30, 2005·Diabetes, Obesity & Metabolism·A J GoudieJ C G Halford
Jan 1, 2010·Drug, Healthcare and Patient Safety·Mario F JuruenaIrismar Reis de Oliveira
Jun 27, 2009·Neuropsychiatric Disease and Treatment·Ann M Mortimer
Mar 25, 2008·Therapeutics and Clinical Risk Management·Philippe NussCédric Tessier
Jul 5, 2008·Clinical Drug Investigation·Luca PaniKöksal Alptekin
Aug 17, 2010·Indian Journal of Pharmacology·Ashish AggarwalR C Jiloha
Apr 3, 2014·Annals of General Psychiatry·Joseph PeuskensAndreas Schreiner
Aug 10, 2012·International Journal of Clinical Pharmacy·Maryam Karimi KhalediChasity M Shelton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here